MRK vs BIIB
By Alex · Tickerpine
Merck & Co., Inc. vs Biogen Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | MRK | BIIB |
|---|---|---|
| Price | $128.66 | $216.03 |
| Market cap | $317.77B | $31.89B |
| P/E ratio | 36.2 | 23.3 |
| ROE | 18.94% | 7.70% |
| Profit margin | 13.59% | 13.80% |
| Revenue growth | 4.90% | 1.90% |
| Dividend yield | 2.64% | — |
| Beta | 0.22 | 0.18 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
MRK vs BIIB in plain English
- MRK is the bigger company — about 10.0× the market cap of BIIB.
- BIIB is cheaper on earnings (P/E 23.3 vs 36.2).
- MRK earns a higher return on equity (19% vs 8%).
- MRK is growing revenue faster (5% vs 2%).
- MRK pays a dividend (2.64%) while the other effectively doesn't.
How would $1,000 have done in each?
MRK return calculator
See what $1,000 in Merck & Co., Inc. would be worth today.
BIIB return calculator
See what $1,000 in Biogen Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.